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Microalbuminuria in humans with Type 1 diabetes (T1D) is associated with increased urinary excretion of megalin, as well as
many megalin ligands, including vitamin-D-binding protein (VDBP). We examined the DBA/2J diabetic mouse, nephropathy
prone model, to determine if megalin and VDBP excretion coincide with the development of diabetic nephropathy. Megalin,
VDBP, and 25-hydroxy-vitamin D (25-OHD) were measured in urine, and genes involved in vitamin D metabolism were assessed
in renal tissues from diabetic and control mice at 10, 15, and 18 weeks following the onset of diabetes. Megalin, VDBP, and 25-
OHD were increased in the urine of diabetic mice. 1-α hydroxylase (CYP27B1) mRNA in the kidney was persistently increased
in diabetic mice, as were several vitamin D-target genes. These studies show that intrarenal vitamin D handling is altered in the
diabetic kidney, and they suggest that in T1D, urinary losses of VDBP may portend risk for intrarenal and extrarenal vitamin D
deﬁciencies.
1.Introduction
Abnormal excretion of protein is a clinically relevant indi-
cator of impending diabetes-related renal damage; however,
mechanisms underlying proteinuria in diabetic nephropathy
associated with type 1 diabetes mellitus (T1D) are not com-
pletely understood. Numerous studies suggest the involve-
ment of the glomerulus wherein cellular damage and glom-
erular basement membrane thickeningis observed[1].How-
ever,proximaltubuledysfunction alsoappearstobeacentral
event in promoting protein loss in the diabetic kidney due
to enhanced sodium reabsorption and decreased protein re-
absorption [1–3].
We have recently shown that megalin and cubilin, two
multiligand coreceptors expressed in the proximal tubules of
the kidney and involved with the reuptake of small-molec-
ular-weight proteins, like albumin, are more abundant in
the urine of humans with T1D and microalbuminuria [4].
Many megalin/cubilin ligands, including vitamin-D-binding
protein, are also elevated in the urine of these individuals
[5]. In support of these ﬁndings in humans with T1D, STZ-
induced T1D in rats results in decreased megalin protein
expression along the apical membrane of the proximal con-
voluted tubules[6]. Thus, loss of megalin/cubilin could con-
tribute to the inability of proximal tubules to adequately
reabsorb many ﬁltered proteins in T1D.
Megalin has been shown to play a central role in vitamin
D metabolism. Megalin is involved in the uptake of the
vitamin-D-binding protein (VDBP)/25-hydroxy vitamin D3
(25-OHD) complex from the glomerular ﬁltrate, where it is
endocytosed by the proximal tubule. In the proximal tubule,
25-OHD is dissociated from VDBP and 1-hydroxylated by
1-α hydroxylase to form 1,25(OH)2D3 (1,25-OHD), which
is returned to the circulation [7]. Thus, reduced uptake of
VDBP/25-OHD by megalin in diabetic nephropathy could
lead to intrarenal losses of VDBP and vitamin D. To better
understand the renal response to and the consequences of
diminished endocytic ligand functioning in the context of
diabetes,wehavestudied,longitudinally,nephropathy-prone
DBA/2J diabetic mice to explore if megalinuria occurs in2 Experimental Diabetes Research
Table 1: Characteristics of DBA2/J mice without (control) and with (diabetes) STZ-induced diabetes.
Parameter
10 weeks of DM 15 weeks of DM 18 weeks of DM∗
DBA/2J
Control
DBA/2J
Diabetes
P value DBA/2J
Control
DBA/2J
Diabetes
P value DBA/2J
Control
DBA/2J
Diabetes
P value
N 10 10 — 10 10 — 13 6 —
Body weight (g) 28.4 ±1.32 4 .2 ± 0.6 .003 30.6 ±0.72 3 .3 ± 0.8 .0001 28.4 ±1.22 2 .8 ± 1.0 .004
Left Kidney wt (g) 0.27 ±0.02 0.29 ± 0.01 NS 0.30 ±0.01 0.30 ± 0.01 NS 0.28 ±0.01 0.34 ± 0.04 .05
Blood glucose
(mg/dl) 104.6 ±6.9 559.1 ±9.4 .0001 136.4 ±9.3 561.9 ± 16.3 .0001 109.9 ±4.9 582.2 ±6.7 .0001
Urine albumin/Cr
(μg/mg) 52.5 ±17.48 8 .0 ± 21.9 .04 67.8 ±15.5 178.3 ± 19.7 .001 18.3 ±3.17 3 .6 ± 19.8 .001
∗Fewer DBA/2J diabetic mice were available to study at 18 weeksdue to increased mortalitywithin this group as described elsewhere [8].
an albuminuric murine model of T1D and if it is associated
with abnormal intrarenal vitamin D homeostasis.
2.Materialsand Methods
2.1. Modeling of Diabetic Nephropathy in DBA/2J Mice.
DBA/2J mice (The Jackson Laboratories, Bar Harbor, ME,
USA)were treated with STZ (40 mg/kg/day × 5d a y sgi v e na t
10-11weeksofage,toinducediabetes)orvehicle(PBS).Mice
were provided ad libitum access to food and water and mon-
itored weekly for glucosuria and weight change as described
elsewhere [8]. Groups of diabetic and control mice were
designated for sacriﬁce at 10, 15, or 18 weeks after the onset
of diabetes. Mice were transferred to individual metabolic
cages for urine collections 24 to 48 hours before sacriﬁce.
At sacriﬁce, trunk blood and kidneys from each animal were
collected. All procedures and protocols were approved by
the Institutional Animal Care and Use Committee at the
University of Arkansas for Medical Sciences.
2.2. Assays. Urine samples were analyzed for microalbumin-
uria (Albuwell M ELISA, Exocell, Philadelphia, PA USA)and
by Western blot for the presence of megalin (Array Genetics,
LLC,Newtown,CT)andVDBP(R&DSystems,Minneapolis,
MN USA). Quantitative dot blotting for urine VDBP was
carried out as described elsewhere [9]. Urinary 25-OHD was
measured in undiluted urine by ELISA (Immunodiagnostics
Systems, Fountain Hills, AZ, USA). Serum intact PTH was
assayed by ELISA (ALPCO, Salem, NH, USA).
2.3. Quantitative Real-Time PCR (qRT-PCR). RNA was
prepared from kidneys, cDNA synthesized, and qRT-PCR
performed as described previously [10]. Primer sets for each
gene of interest (megalin, cubilin, Txnip, 1-α hydroxylase,
calbindin D-9k, and Calbindin D-28k) are included in
Table 1 in Supplementary material available at doi:10.1155/
2011/269378.
2.4. Statistical Analyses. Statistical analyses were performed
using GraphPad PRISM 5.02 software. The Mann-Whitney
test was used to ascertain diﬀerences between groups, and
data are presented as mean ± standard error of the mean.
Linear relationships between data sets were analyzed using
the Pearson Product Moment Correlation. Statistical signifi-
cance was deﬁned as P<. 05.
3.Results
Diabetic DBA/2J(STZ-treated) mice assessed at 10, 15, or 18
weeks of diabetes demonstrated severe hyperglycemia, albu-
minuria (increased albumin/Cr), and weight loss; renal size
was signiﬁcantly increased at 18 weeks of diabetes (Table 1).
These data are consistent with the ﬁndings of Qi et al. [8]
showing that diabetic DBA/2J mice exhibit early and per-
sistent abnormal protein excretion rates and nephromegaly
(i.e., nephropathy prone).
Pooled urine from DBA/2J diabetic urine contained im-
munoreactive megalin at all time points, yet no megalin was
detected in the urine from control animals at any time point
(Figure 1(a)). Little to no full-length megalin (660kDa) was
detected, suggesting that megalin was excreted primarily as a
cleavedproduct,consistentwithmegalinfragmentsobserved
in human urine [11]. Renal expression of megalin mRNA
was also assessed in control and diabetic DBA/2J mice.
Figure 1(b) shows that megalin gene expression was similar
in control and diabetic kidneys at 10 and 15 weeks after the
onset of diabetes. In contrast, after 18 weeks of diabetes,
megalin expression increased signiﬁcantly in the diabetic
animals. Megalin and cubilin function as co-receptors in-
volved in the uptake and endocytosis of many small-mo-
lecular-weight proteins in the proximal tubule. Figure 1(c)
shows that renal gene expression of the co-receptors megalin
and cubilin in DBA/2J kidneys (10–18 weeks) is highly
correlated (r = 0.8284; P<. 0001).
Vitamin-D-binding protein (VDBP) uptake in the prox-
imal tubule is principally controlled by megalin [12]. There-
fore, ifmegalin loss offunction occursin the diabetickidney,
then VDBP might be found in greater abundance in the
urine of diabetic mice. VDBP was detected at its predicted
molecular mass of ∼52KDa in pooled urine of diabetic an-
imals by Western blotting (Figure 2(a)). Little or no VDBP
was detected in control urines. VDBP was then assessed by
semiquantitative dot blotting in individual urine samples
from control and diabetic mice. After 10 weeks of dia-
betes, diabetic animals excreted elevated amounts of VDBPExperimental Diabetes Research 3
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Figure 1: (a) Immunoblotting for the detection of megalin, in the pooled urine of DBA/2J mice without diabetes (CON) or with diabetes
(STZ) for 10-, 15-, or 18-week duration (n = 6 mice/group, containing equal amounts of creatinine (Cr) for each sample (2.0μg Cr/lane)).
(b) Megalin gene expression as determined by qRT-PCR in renal tissue from control and diabetic DBA/2J mice at 10-, 15-, and 18-
week duration. (c) Correlation of megalin and cubilin gene expression in kidneys from diabetic DBA/2J mice (10, 15, and 18 weeks).
Immunoblotting and qRT-PCR were carried out as described in Section 2.
(Figure 2(b)). Because VDBP excretion in the megalin-
null mouse has been associated with urinary losses of 25-
OHD, urinary 25-OHD was assessed. Diabetic DBA/2J mice
excreted signiﬁcantly higher amounts of 25-OHD than did
control mice after 10 weeks of diabetes (Figure 2(b)). There
was a signiﬁcant association between urinary VDBP, and
urinary 25-OHD in diabetic mice (Figure 2(c); r = 0.5577;
P = .0162); however, no signiﬁcant correlation was found
betweenurinary VDBPandurinary 25-OHDincontrolmice
(r =− 0.06; P = .8). Together, these data show that neph-
ropathy-prone diabetic DBA/2J mice experience early and
persistent urinary losses of VDBP and 25-OHD.
Because the diabetic DBA/2J mouse excretes signiﬁcant
amounts of megalin, VDBP and 25-OHD, we next examined
renal genes involved in vitamin D metabolism. Figure 3(a)
shows that 1-α hydroxylase, which converts 25-OHD into
1,25-OHD, was upregulated in kidneys of diabetic mice at all
three timepointsexamined. BecausePTH regulates renal1-α
hydroxylase expression, serum PTH was measured in control
and diabetic mice at all time points. PTH values were more4 Experimental Diabetes Research
variable in the diabetic animals, but no statistical diﬀerence
was found between control and diabetic mice at 10, 15,
or 18 weeks after the onset of diabetes (see Supplementary
Figure 1).Renalexpression of24-hydroxylase wasnotaltered
at any time point in diabetic mice (data not shown).
Because the upregulation of 1-α hydroxylase in the
DBA/2J diabetic kidney might portend intracellular accu-
mulation of 1,25-OHD, target genes of 1,25-OHD were also
assessed in these mice. Figures 3(b)–3(d) show three target
genes known to be regulated by 1,25-OHD in the kidney:
thioredoxin-interaction protein (txnip, also known as vita-
min D up-regulated protein), calbindin D-9k and calbindin
D-28k [13]. All were up-regulated in their expression in
the kidneys of diabetic mice. Furthermore, both calbindin
species were highly correlated in their levels of expression,
suggesting a common pathway of regulation (r = 0.7555,
P<. 0001).
4.Discussion
Megalin and its coreceptor cubilin function as endocytic
receptors for an extensive list of ligands including albumin,
vitamin-carrier proteins, lipoproteins, hormones, enzymes,
immune-related proteins, and drugs [14]. Thus, alterations
in the expression or activity of megalin and/or cubilin may
lead to a number of pathological consequences. Megalin-
knockout mice exhibit albuminuria as well as urinary losses
of low-molecular-weight proteins, including VDBP [15]. In
humans, mutations in megalin cause Donnai-Barrow and
facio-oculo-acoustico-renal syndrome [16]. These individ-
uals display several phenotypic characteristics similar to
megalin knockout animals, including renal disease, protein-
uria, and increased urinary VDBP levels. Megalin dysfunc-
tion has also been demonstrated in Dent disease, caused by
am u t a t i o ni nt h ec h l o r i d ec h a n n e lCLCN5,w h i c hr e s u l t s
in low-molecular-weight proteinuria and urinary VDBP loss
in humans, similar to mice deﬁcient in the CLCN5 gene
and protein product, CLC-5 [17]. Similarly, we have recently
demonstrated increased urinary loses of megalin/cubilin
and VDBP in humans with T1D and microalbuminuria [4,
5], suggesting that intrarenal dysregulation of the vita-
min D pathway in T1D may mimic that observed in other
conditions in which the megalin-mediated endocytosis is
disrupted.
We have studied the renal response to T1D in the neph-
ropathy-prone diabetic DBA/2J mouse and have demon-
strated that megalin and VDBP are both lost over time
in the urine of diabetic animals. Mechanisms involved in
the renal loss of megalin and megalin ligands are currently
poorly understood; however, previous studies have shown
that megalin can be shed from cell surfaces by matrix met-
alloproteinase activity [18, 19]. Interestingly, MMP activity
is elevated in urine from T1D subjects [20]a n di nt h e
DBA/2J diabetic mouse (data not shown). Thus, enhanced
MMP activity in the parenchyma and/or tubular lumen of
the diabetic kidney may result in excess shedding and loss of
megalinfromproximaltubulecellsurfaces. Asaconsequence
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Figure 2: (a) Immunoblotting for the detection of VDBP in the
pooled urine of DBA/2J mice without diabetes (CON) or with
diabetes (STZ)for10-,15-,or18-weekduration(n = 6mic e/gr oup ,
containingequal amountsofcreatinine(Cr) foreach sample(2.0μg
Cr/lane)). (b) VDBP in urine of control and diabetic mice was
assessed by semiquantitative dot blotting, and urine 25-OHD was
assayed by ELISA in urine of control and diabetic mice as described
inSection 2.(c)C orr elationofVDBPand25-OHDassay edinurine
from diabetic DBA/2J mice (10, 15, and 18 weeks—see legend).
of megalin deﬁciency, the megalin ligand, VDBP, and 25-
OHD are also lost in the urine of diabetic DBA/2J mice.
This is similar to what has been reported for the megalin
null mouse and the CLC-5-deﬁcient mouse. Taken together,
these data support the concept that impairment of megalin-
mediated endocytosis results in the loss of the VDBP/25-
OHD complex, irrespective of the underlying cause for meg-
alin dysfunction.Experimental Diabetes Research 5
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Figure 3: (a) 1-α hydroxylase, (b) TXNIP, (c) calbindin D9k, and (d) calbindin D28k gene expression as determined by qRT-PCR in renal
tissue from control (CON) and diabetic (STZ) DBA/2J mice at 10-, 15-, and 18-week duration. Quantitative RT-PCR was carried out as
described in Section 2.
Insulin deﬁciency, streptozotocin, and/or hyperglycemia
could also be potential mediators involved in the loss of
megalin ligands, such as VDBP and 25-OHD. To address
these variables, we have studied albuminuria and VDBP
in the urine from long-term diabetic C57B/6 mice, which
do not develop renal pathology, yet develop hyperglycemia,
secondary to insulin deﬁciency after STZ injection, just as
the DBA/2Jdiabetic mouse does [8]. Unlike diabetic DBA/2J
mice, no signiﬁcant albuminuria or enhanced urinary VDBP
excretionwas observed indiabetic C57B/6mice compared to
control mice (see Supplementary Table 2); yet the diabetic
C 5 7 B / 6m i c ew e r ee x p o s e dt oS T Z ,e x p e r i e n c e dl o s so f
beta cell function, and had signiﬁcant hyperglycemia as was
observedinthediabeticDBA/2Jmice,suggestingthatinsulin
deﬁciency, STZ, or hyperglycemia is not directly causal to
VDBP urinary losses.
Renal expression of 1-α hydroxylase is signiﬁcantly ele-
vated in the diabetic DBA/2Jmouse; however, several studies
have shown in rodent models of STZ-induced diabetes
that circulating concentrations of 1,25-OHD are typically
decreased [21, 22]. Similarly, the megalin knockout mouse
and the CLC-5 knockout mouse demonstrate elevated renal
expression of 1-α hydroxylase, yet, surprisingly manifest low
circulating concentrations of 1,25-OHD [23, 24]. Further-
more, circulating PTH, a primary regulator of renal 1-α
hydroxylase expression, is not elevated in megalin knock-
out mice, CLC-5 knock-out mice, or in DBA/2J diabetic
mice. The mechanism behind the paradoxical ﬁnding of
elevated intrarenal 1-α hydroxylase expression in the context
of megalin dysfunction has been addressed by Maritzen et
al. [24]. In this paradigm, PTH, which is normally retrieved
from the urine by megalin, is present at higher concentra-
tions in the lumen of the late proximal tubule, where it
activates luminal PTH receptors to increase 1-α hydroxylase
activity. However, because 25-OHD/VDBP complexes are
not eﬃcientlyendocytosedbytheproximal tubulesecondary
to megalin dysfunction, lack of substrate leads eventually
to diminished 1,25-OHD production. Furthermore, this
paradigm predicts that increased concentrations of vita-
min D in the lumen of the distal tubule would result in6 Experimental Diabetes Research
transcriptional upregulation of vitamin D responsive genes.
Indeed, several vitamin D responsive genes (i.e., calbindin
D-9k,calbindin D-28k,and thioredoxin-interaction protein)
were all signiﬁcantly increased in the kidneys of diabetic
mice, similar to what is observed in CLC-5 knock-out mice
[24]. Interestingly, calbindin D-28k has been shown to be
overexpressed in the distal tubules of diabetic mice [25].
Vitamin D is now appreciated as a pleiotropic hormone
having aﬀectsonmultipletissues and cells[26]. Ourﬁndings
in diabetic mice and humans [5]o fr e n a lw a s t i n go fV D B P
suggest that abnormal renal metabolism of vitamin D in
T1D may have important and broad-spectrum implications.
Forinstance, osteoporosis and fractures are common in T1D
[27], as are cardiovascular comorbidities, all of which have
beenassociated with vitamin Ddeﬁciency/insuﬃciency[26].
In addition to the beneﬁcial systemic aﬀects of vitamin D,
vitamin D analogs have been shown to preventrenal damage
inT1D[28];however,inthesetting ofVDBP/25-OHDlosses
in T1D, vitamin D analog therapy may prove to be less
eﬀective. In summary, these studies suggest a mechanism
by which intrarenal vitamin D handling and metabolism
is altered in diabetic kidney disease, and they signify that
urinary losses of VDBP in T1D portend a risk for intrarenal
and systemic vitamin D deﬁciencies.
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